Krystal Biotech Stock Plunges 12%, Wiping Out $1.2 Billion, As Profit Falls Despite $400 Million Buyback
Third-quarter net income fell to $63.1 million on a tax swing, and management pushed back clinical readouts.
Krystal Biotech, the gene-therapy maker behind the skin-disease treatment VYJUVEK, saw its shares plunge 11.72% to $293.35 in Monday trading, as of 9:55 a.m. ET, erasing about $1.2 billion in market value. The drop came on the day it reported lower third-quarter net income and told analysts on its call that clinical readouts will arrive later than planned.
A tax swing cuts profit
Net income fell to $63.1 million, as a $17.1 million tax expense replaced a $31.4 million tax benefit booked a year earlier, according to the company's 10-Q.
The company also authorized a buyback of up to $400 million. On the earnings call, management said the shares trade below intrinsic value, and it pushed back the timing of clinical readouts.
The stock was on pace for its biggest one-day drop in at least 274 trading sessions, since Sept. 30, 2025.
VYJUVEK still growing
Krystal discovers, develops and makes gene therapies, which deliver working copies of genes to a patient's cells. VYJUVEK, a topical treatment for dystrophic epidermolysis bullosa, a rare skin disease, generated $127.3 million in sales, up 30% from a year earlier. Cumulative sales since launch reached $1.1 billion.
VYJUVEK's gross margin was 94% in the third quarter, the company said in its earnings release.
Before Monday's fall, the shares were up about 35% year to date at Friday's close, against about 11% for the S&P 500.
The company expects interim results from its HALITE-1 safety study of KB111 in Hailey-Hailey disease before the end of 2026.
Sources
- Krystal Biotech GAAP EPS of $2.05 beats by $0.28, revenue of $1.1B beats by $973.46M — seekingalpha.com
- Krystal Biotech Announces Third Quarter 2026 Financial and — rss.globenewswire.com
- The company's filing (Krystal Biotech) — SEC filing
- Krystal Biotech — Form 10-Q for the quarter ended 2026-09-30 (quarterly results) — SEC EDGAR